Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silodosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 20/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 20/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silodosin SCHEMBL31017646 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL1533433 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL29967021 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL10327491 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL8543706 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL8539364 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422042 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422051 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422170 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16422017 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3266 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079854-A | Preparation method of silodosin dehydrogenation impurity standard | — | 2026-05-26 | — | — | CN | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260053797-A1 | METHOD AND FORMULATION FOR TREATING MALE PREMATURE EJACULATION | Zyvran Pharmaceuticals Inc. (US) | 2026-02-26 | — | — | US | claimed |
| EP-3930839-B1 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | CARDIFF ONCOLOGY INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4622633-A1 | MODIFIED-RELEASE SILODOSIN COMPOSITIONS AND USE THEREOF IN METHODS FOR MALE CONTRACEPTION | Pharmajor Incorporated (US) | 2025-10-01 | — | — | EP | claimed |
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4608388-A1 | COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES FOR OBESITY AND OTHER DISEASES | STARROCK PHARMA INC. (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4603095-A2 | IMPROVED PHARMACEUTICAL FORMULATIONS | Ferring B.V. (NL) | 2025-08-20 | — | — | EP | claimed |
| US-20250222008-A1 | EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION | TSUBOTA LABORATORY, INC. (JP) | 2025-07-10 | — | — | US | claimed |
| EP-4580632-A2 | METHODS OF USING ITRACONAZOLE DRY POWDERS | Pulmatrix Operating Company, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2005027923-A1 | USE OF VITAMIN D3 ANALOGUE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | BIOXELL SPA (IT) | 2005-03-31 | — | — | WO | claimed |
| US-20050065124-A1 | Method for treating benign prostatic hyperplasia | BIOXELL S.P.A. (IT) | 2005-03-24 | — | — | US | claimed |
| EP-1505981-A2 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1293198-B1 | Device for transdermal administration for the treatment of urinary tract disorders | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-02-09 | — | — | EP | claimed |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| US-20040132697-A1 | Treatment of female sexual dysfunction | PFIZER INC. | 2004-07-08 | — | — | US | claimed |
| WO-2004041259-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-05-21 | — | — | WO | claimed |
| WO-2004026300-A1 | COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2004-04-01 | — | — | WO | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| WO-2003094921-A2 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-20 | — | — | WO | claimed |